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Introduction. Reduced kidney function, approximated by elevated cystatin C, is associated with diastolic dysfunction, heart failure,
and cardiovascular mortality; however, the precise mechanism(s) that account for these relationships remains unclear. Under-
standingtherelationshipbetweencystatinCandsubclinicalleftventricular(LV)remodeling,acrossethnicallydiversepopulations,
mayhelpexplainthemechanismsunderlyingtheassociationofkidneydysfunctionwithheartfailureandcardiovascularmortality.
Methods. MeasuresofcystatinCandLVparameterswereobtainedfromthemulti-ethnicstudyofatherosclerosis(MESA)cohortat
baseline(N = 4,970withcompletedataoncystatinCandLVparameters).LVparameters;LVend-diastolic(LVEDV)andend-sys-
tolic volumes (LVESV), LV mass (LVM), concentricity (LV mass/LV end-diastolic volume), and LV ejection fraction (LVEF) were
measuredusingmagneticresonanceimaging.Nestedlinearmodelswereusedtoexaminetherelationshipbetweenhigherquartiles
of cystatin C and LV parameters, with and without adjustment for demographics, height, and weight, and traditional cardiovas-
cular risk factors. Similar analyses were performed stratiﬁed by ethnicity and gender. Results. A fully adjusted model demonstrated
a linear relationship between higher quartiles of cystatin C and lower LVEDV, (Mean±SE, 128±0.7, 128±0.7, 126±0.7,
124±0.8mL;P = 0.0001).AssociationswerealsoobservedbetweenhigherquartilesofcystatinCandlowerLVESV(P = 0.04)and
concentricity (P = 0.0001). In contrast, no association was detected between cystatin C and LVM or LVEF. In analyses stratiﬁed by
race and gender, the patterns of association between cystatin C quartiles and LV parameters were qualitatively similar to the overall
association. Conclusion. Cystatin C levels were inversely associated with LVEDV and LVESV with a disproportionate decrease in
LVEDVcomparedtoLVMinamulti-ethnicpopulation.Thismorphometricpatternofconcentricleftventricularremodeling,may
in part explain the process by which kidney dysfunction leads to diastolic dysfunction, heart failure and cardiovascular mortality.
1.Introduction
Elevated cystatin C, a marker of reduced kidney function,
is associated with increased cardiovascular mortality [1]a n d
incident heart failure [2–4]. Cystatin C has been shown to be
a superior marker of renal function compared to creatinine
or estimated GFR as it is less aﬀected by age, gender, and
ethnicity [5–8]. Moreover, higher levels of cystatin C have
been shown to be associated with increased LV mass [9],
concentric LV hypertrophy [9, 10], and diastolic dysfunction
[11]. An association between cystatin C and heart failure,
particularly diastolic heart failure, is not unexpected given
that it is a sensitive and speciﬁc marker of renal insuﬃciency
andhighlycorrelateswithhypertension[9];however,various2 International Journal of Nephrology
lines of evidence suggest that the relationship between cys-
tatin C and LV mass and hypertrophy may go beyond sim-
ple confounding due to its association with hypertension
[11]. Data are needed to better deﬁne the relationship bet-
ween cystatin C and ventricular remodeling, which may clar-
ify its relationship with heart failure and cardiovascular mor-
tality and elucidate new mechanisms which may lead to
development of novel therapies. Further, this will clarify the
process by which mild-moderate kidney dysfunction may
lead to ventricular remodeling and heart failure. We hypoth-
esize that cystatin C is a marker for ventricular remodeling,
independentofbloodpressure,inamulti-ethnic population.
2.MaterialsandMethods
2.1.StudyPopulation. TheMulti-EthnicStudyofAtheroscle-
rosis (MESA) design has been previously described [12].
Brieﬂy, MESA is a prospective cohort study that began in
July 2000 to investigate the prevalence, correlates, and pro-
gressionofsubclinicalCVD.Thestudyincluded6814racially
diverse men and women aged 44–84 years old recruited from
6 US communities (Baltimore, Md; Chicago, Ill; Forsyth
County, NC; Los Angeles County, Calif; northern Manhat-
tan, NY; and St. Paul, Minn). MESA cohort participants
were 38% Caucasian (n = 2,622), 28% African-American
(n = 1,893), 22% Hispanic (n = 1,496), and 12% Chinese
(n = 803). Individuals with a history of physician-diagnosed
myocardial infarction, angina, heart failure, stroke, or tran-
sientischemicattack,orwhohadundergoneaninvasivepro-
cedure for CVD (coronary artery bypass graft, angioplasty,
valve replacement, pacemaker placement, or other vascular
surgeries) were excluded from the study at baseline (2000–
2002). This study was approved by the Institutional Review
Boards of each study site, and written informed consent was
obtained from all participants.
2.2. Laboratory Measures and Data Collection. Medical his-
tory, anthropometric measurements, and laboratory data for
thepresentstudyweretakenfromtheﬁrstexaminationofthe
MESA cohort (July 2000–August 2002). Information about
age, sex, ethnicity, and medical history was obtained by
questionnaires. Resting blood pressure was measured using
Dinamap Monitor PRO 100 (Critikon, Tampa, Fl) auto-
mated oscillometric device. Three measurements were ob-
tained at 1-minute intervals with the subject in the seated
position with back and arm supported after 5min of rest
with an appropriate-sized cuﬀ, with the cuﬀ at the level
of the heart, using a standardized protocol. The average of
the second and third measurements was recorded as the
restingbloodpressure.Hypertensionwasdeﬁnedasasystolic
blood pressure ≥140mmHg, a diastolic blood pressure
≥90mmHg, or currently taking medications for blood pres-
sure control. Smoking use was deﬁned as never, former, and
current smokers. Diabetes was deﬁned as a fasting glucose
≥126mg/dL or use of insulin or hypoglycemic medications.
Total cholesterol was measured from blood samples obtained
after a 12-hour fast and measured using a standardized kit
(Roche Diagnostics). Cystatin C was measured from frozen
sera at a central laboratory (University of Vermont, Colch-
ester, Vt) using a BNII nephelometer (Dade Behring Inc,
Deerﬁeld, Ill) and a particle-enhanced immunonephelomet-
ric assay (N Latex Cystatin C; Dade-Behring) [13]. The
analytical coeﬃcient of variation for this assay is 2.5%.
2.3. Magnetic Resonance Imaging Protocol. The MESA MRI
protocol has been described in detail elsewhere [14]. Brieﬂy,
cardiacMRItestingwasperformedatMESAstudysitesusing
a standard protocol and read at a central site (Johns Hopkins
University, Baltimore, MD). LVEDV and LVESV, LVM and
LVEF were determined using 1.5-Tesla MR scanners: Signa
LX and CVi (GE Medical Systems, Waukesha, Wis) and Sym-
phony and Sonata (Siemens Medical Systems, Erlangen,
Germany). MRI was performed with a 4-element phased-
array surface coil placed anteriorly and posteriorly, with
electrocardiogram gating and brachial artery blood pressure
monitoring. Imaging consisted of cine images of the left ven-
tricle with a temporal resolution of 50 milliseconds or less.
LVEDVandLVESVwerecalculatedusingSimpson’srule(the
summation of areas on each separate slice multiplied by the
sum of slice thickness and image gap). LVM was determined
by the sum of the myocardial area (the diﬀerence between
endocardial and epicardial contour) times slice thickness
plus image gap in the end-diastolic phase multiplied by
the speciﬁc gravity of myocardium (1.05g/mL). LVEF was
calculated as LV stroke volume divided by LVEDV multiplied
by 100. Concentricity was determined by obtaining a ratio of
LVM by LVEDV. The interobserver variability in estimating
LV parameters was: LVEDV, technical error of the mean
(TEM%, 95% CI), (4.4mL, 95% CI 2.6, 6.6); LVESV
(12.8mL, 95% CI 9.3, 16.2); LVM (6.0gm, 95% CI, 4.6, 7.4);
LVEF (5.1%, 95% CI 3.6, 6.7) and intraobserver variability
in estimating LV parameters was: LVEDV (5.1mL, 95% CI,
3.94, 6.15); LVESV (10.5mL, 95% CI, 8.17, 12.68); LVM
(6.3gm,95%CI,5.17,7.38);LVEF(3.9%,95%CI,3.06,4.72)
[14].
2.4. Statistical Methods. Diﬀerences in baseline characteris-
ticswerecomparedacrossquartilesusinganalysisofvariance
(ANOVA) for continuous variables and Chi-square tests for
categorical variables. The LV parameters of interest, LVEDV,
LVESV, LVM, LVEF, and concentricity (LVM/LVEDV), were
compared across cystatin C quartiles using ANOVA.
Multivariate linear regression analyses in nested models
were performed to evaluate the association of cystatin C
quartiles, with the following outcomes: LVEDV, LVESV,
LVM, LVEF, and concentricity (LVM/LVEDV).After univari-
ate analysis (Model 1), the following covariates were con-
sidered as potential confounders: age, gender, race/ethnicity,
height, and weight (Model 2); Model 2 covariates plus tradi-
tional cardiovascular risk factors: history of diabetes, antidi-
abetic medications, hypertension, systolic blood pressure,
total cholesterol, antilipid medications, and smoking (Model
3). Similar linear analyses in nested models were performed
stratiﬁed by ethnicity and gender. Interaction terms using
(cystatin C quartile × race) and (cystatin C quartile × gen-
der) were introduced in the model.International Journal of Nephrology 3
Table 1: Baseline characteristics of 4,970 MESA participants by quartile of cystatin C.
Variables Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value
Demographics
(n = 4,970) (n = 1,347) (n = 1,356) (n = 1,150) (n = 1,117)
Age, in years 56.5 (8.6) 59.7 (9.3) 63.4 (9.3) 67.8 (9.6) <0.0001
Male 511 (38%) 647 (48%) 621 (54%) 591 (53%) <0.0001
Female 836 (62%) 709 (52%) 529 (46%) 526 (47%) <0.0001
Caucasian 453 (33%) 505 (37%) 484 (42%) 501 (45%) <0.0001
Chinese 234 (17%) 172 (13%) 129 (11%) 116 (10%) <0.0001
African 384 (29%) 359 (26%) 257 (22%) 274 (25%) <0.003
Hispanic 276 (20%) 320 (24%) 280 (24%) 226 (20%) <0.024
Medical history
HTN 425 (32%) 491 (36%) 524 (46%) 669 (60%) <0.0001
Diabetes 142 (11%) 120 (9%) 95 (8%) 155 (14%) <0.0001
Current smokers 158 (12%) 165 (12%) 151 (13%) 157 (14%) <0.31
Renal disease (self-report) 20 (1.5%) 17 (1.3%) 31 (2.7%) 45 (4.0%) 0.0001
Laboratory/clinical parameters
Creatinine mg/dL 0.84 (0.2) 0.91 (0.2) 0.97 (0.2) 1.13 (0.5) <0.0001
GFR MDRDmL/min/1.73m2 91.8 (16.0) 84.0 (14.2) 78.4 (13.5) 67.8 (16.0) <0.0001
Systolic BP, mmHg 121.2 (20.2) 123.8 (20.0) 126.7 (21.0) 131.4 (22.9) <0.0001
Diastolic BP, mmHg 71.5 (10.5) 72.3 (10.2) 72.0 (9.9) 71.6 (10.6) 0.19
Body mass index Kg/m2 26.7 (4.8) 27.5 (4.7) 28.2 (4.9) 28.8 (5.2) <0.0001
Body surface area m2 1.80 (0.2) 1.85 (0.2) 1.87 (0.2) 1.88 (0.2) <0.0001
Medications
Antihypertensive meds 322 (24%) 414 (31%) 421 (37%) 598 (54%) <0.0001
Beta-blockers 70 (5%) 86 (6%) 110 (10%) 157 (14%) <0.0001
ACE inhibitors 107 (8%) 113 (8%) 122 (11%) 199 (18%) <0.0001
ARB 23 (2%) 41 (3%) 30 (3%) 67 (6%) <0.0001
Calcium channel blockers 127 (9%) 146 (11%) 145 (13%) 174 (16%) <0.0001
Thiazide diuretics 47 (3%) 70 (5%) 79 (7%) 126 (11%) <0.0001
Loop diuretics 10 (1%) 11 (1%) 15 (1%) 40 (4%) <0.0001
Continuous variables as mean (standard deviation) and categorical variables as percentages; P value obtained using analysis of variance and chi-square test
across cystatin C quartiles. cystatin C quartiles 1: ≤0.76, quartile 2: >0.76 & ≤0.86, quartile 3: >0.86 & ≤0.98, quartile 4: >0.98 in mg/dL; HTN: hypertension;
GFR: glomerular ﬁltration rate; MDRD: modiﬁcation of diet in renal disease; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker.
In a separate analysis, where serum creatinine or creat-
inine-based estimated glomerular ﬁltration rate (eGFR-CR)
was added in the model to assess the association of cystatin
C quartiles with LV parameters, collinearity diagnostics such
as variance inﬂation factor was performed to avoid unstable
parameter estimates. Sensitivity analysis between log trans-
formed cystatin C and LV parameters was also performed.
All statistical analyses were performed using JMP Version 8
(SAS Institute Inc., Cary, North Carolina).
3. Results
3.1. Baseline Characteristics by Cystatin C Quartiles. Of 6,814
MESA participants, 1,786 did not have MRI measures of LV
structure and function, and 58 had no serum cystatin C
measures, leaving 4,970 participants who were included at
baseline for analysis. Cystatin C levels ranged from 0.36 to
7.59mg/L with a mean value of 0.89mg/L and a median
of 0.86mg/L (interquartile range: 0.76 to 0.98mg/L). For
ease of comparability with previous studies, cystatin C was
divided into quartiles: quartile 1 (≤0.76mg/L), quartile 2
(>0.76 and ≤0.86mg/L), quartile 3 (>0.86 and ≤0.98mg/L),
and quartile 4 (>0.98mg/L). Participants with higher con-
centrations of cystatin C were more likely to be older, to have
diabetes and hypertension, and to use antihypertensive med-
ications. Those with higher cystatin C levels were less likely
to be Chinese or black and had higher body mass indices. As
expected, increasing quartiles of cystatin C were associated
with higher levels of creatinine and lower creatinine-based
estimated glomerular ﬁltration rates (Table 1).
3.2. Cystatin C Quartiles and LV Parameters. The unadjusted
associations and P values for trend between higher cystatin
C quartiles and MRI measures of LV remodeling are demon-
strated in Table 2. In a multivariate linear analysis, adjusting
for age, gender, race/ethnicity, height, and weight (Model 2),
increasingquartilesofcystatinCweresigniﬁcantlyassociated
with LVEDV and concentricity. This association remained
after further adjustment for history of diabetes, antidiabetic4 International Journal of Nephrology
Table 2: The association of cystatin C with LV parameters in nested models showing P trend with increasing cystatin C quartiles.
Outcomes variables Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend
Model 1 (n = 4,970)
LVEDV, ML 125.7 ±0.8 128.7 ±0.9 127.0 ±0.9 123.9 ±1.00 . 1 2
LVESV, ML 39.5 ±0.44 1 ±0.54 0 .2 ±0.53 9 .2 ±0.50 . 5 5
LVM, Gm 138.0 ±1.0 144.8 ±1.1 148.2 ±1.2 151.9 ±1.2 0.0001
LVM/LVEDV, Gm/ML 1.11 ±0.01 1.14 ±0.01 1.19 ±0.01 1.25 ±0.01 0.0001
EF, % 69.2 ±0.26 8 .8 ±0.26 9 .0 ±0.26 9 .2 ±0.20 . 9 0
Model 2 (n = 4,970)
LVEDV, ML 128.1 ±0.7 127.5 ±0.7 125.5 ±0.7 124.3 ±0.8 0.0002
LVESV, ML 40.1 ±0.44 0 .1 ±0.43 9 .2 ±0.43 9 .2 ±0.50 . 0 7
LVM, Gm 145.7 ±0.8 145.1 ±0.8 144.9 ±0.8 148.0 ±0.90 . 1 2
LVM/LVEDV, Gm/ML 1.15 ±0.01 1.15 ±0.01 1.17 ±0.01 1.21 ±0.01 0.0001
EF, % 69.4 ±0.26 9 .3 ±0.26 9 .4 ±0.26 9 .2 ±0.20 . 7 1
Model 3 (n = 4,946)
LVEDV, ML 128.2 ±0.7 127.6 ±0.7 125.5 ±0.7 124.0 ±0.8 0.0001
LVESV, ML 40.1 ±0.44 0 .1 ±0.43 9 .1 ±0.43 9 .0 ±0.50 . 0 4
LVM, Gm 146.1 ±0.8 145.7 ±0.7 145.3 ±0.8 147.3 ±0.80 . 4 5
LVM/LVEDV, Gm/ML 1.15 ±0.01 1.16 ±0.01 1.17 ±0.01 1.21 ±0.01 0.0001
EF, % 69.5 ±0.26 9 .3 ±0.26 9 .5 ±0.26 9 .3 ±0.20 . 7 5
Cystatin C quartiles 1: ≤0.76, quartile 2: >0.76 & ≤0.86, quartile 3: >0.86 & ≤0.98, quartile 4: >0.98 in mg/dL; LV parameters in adjusted least square mean
± standard error. LVEDV: LV end diastolic volume; LVESV: LV end systolic volume; LVM: LV mass; LVM/LVEDV: LV concentricity; EF: ejection fraction
(fraction).
Model1univariateanalysis;Model2adjustedforage,race/ethnicity,gender,height,andweight;Model3adjustedforModel2plusdiabetes,useofantidiabetic
medications, hypertension history, systolic blood pressure, total cholesterol, antilipid medications, and smoking.
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Figure 1: P trend in a fully adjusted model between Cystatin C
quartiles and LVEDV and LVM in the MESA cohort (2000–2002).
CystatinCQuartiles1: ≤0.76,Quartile2:>0.76& ≤0.86,Quartile3:
>0.86& ≤0.98,Quartile4:>0.98;LVEDV,LVEndDiastolicVolume;
LVM, LV Mass; Model adjusted for age, gender, race/ethnicity,
height, weight, diabetes, use of anti-diabetic medications, hyper-
tension history, systolic blood pressure, total cholesterol, anti-lipid
medications, and smoking.
medications, hypertension, systolic blood pressure, antihy-
pertensive medications, total cholesterol, antilipid medica-
tions, and smoking (Model 3) (Figure 1). There was no
relationship between cystatin C and LVM or EF in a fully
adjusted model (Figure 1). Next, we assessed the inﬂuence
of race/ethnicity and gender on the associations between
cystatin C quartiles and LV parameters in a fully adjusted
model. The associations observed between cystatin C and LV
parameters were qualitatively similar within race subgroups
and in both genders.
In a separate analysis after further adjustment for serum
creatinine, the association between cystatin C quartiles and
LV remodeling (LVEDV P = 0.0001, LVESV P = 0.04, and
LVM/LVEDV P = 0.0001) remained highly signiﬁcant. The
resultsofcollinearitydiagnosticsrevealedavarianceinﬂation
factor (VIF) of 1.14 for both creatinine and cystatin C, with
creatinine and cystatin C in the model, and a VIF of 1.37 and
1.47, for creatinine and cystatin C, respectively, in the full
model.
In another separate analysis, after further adjustment for
creatinine-estimated GFR (eGFR-CR) instead of creatinine
in the full model, associations between cystatin C quartiles
and LV parameters: LVEDV (P = 0.0004), LVESV (P =
0.03), and LVM/LVEDV (P = 0.0001) remained highly
signiﬁcant. The results of collinearity diagnostics revealed a
variance inﬂation factor(VIF) of 1.33 forboth eGFR-CR and
cystatin C, with only eGFR-CR and cystatin C in the model,
and a VIF of 1.55 and 1.66, for eGFR-CR and cystatin C,
respectively, in the full model. The associations between log
transformed cystatin C and LV parameters were similar, and
hence data was not presented.
4. Discussion
In this large, ethnically diverse population of 4,970 indi-
viduals of ages 44–84, free of cardiovascular disease, cys-
tatin C was inversely associated with LV end-diastolic andInternational Journal of Nephrology 5
end-systolicvolumesanddirectlyassociatedwithconcentric-
ity independent of hypertension, antihypertensive medica-
tions, and traditional cardiovascular risk factors. The asso-
ciation observed between cystatin C and LV parameters was
not modiﬁed by ethnicity or gender. No association was
demonstrated between cystatin C and LV end-diastolic mass
and LV ejection fraction overall in the population or when
stratiﬁed by ethnicity and gender.
Ventricular remodeling is a broad term which refers to
deviation of normal cardiac structure with notable changes
in chamber volumes, wall thickness, and shape [15]. Ventric-
ular remodeling is inﬂuenced by the type and duration of
cardiovascular injury, and genetic inﬂuences [16]. Ventricu-
lar remodeling incorporates various morphometric patterns
including concentric LV remodeling (increased ratio of LV
mass to end-diastolic volume) [17]. Progressive concentric
LV remodeling is a key feature of diastolic dysfunction [18],
diastolicheartfailure[19],andcardiovascularmorbidityand
mortality [20, 21].
In the Heart and Soul cohort [4, 11] with echocardio-
graphic measures of LV structure in approximately 800 par-
ticipants with coronary artery disease, cystatin C was associ-
atedwithLVhypertrophy,diastolicdysfunction,andincident
heart failure. However, the relationship between cystatin C
a n dL Vv o l u m e sw a sn o te v a l u a t e d .S i m i l a r l y ,P a t e le ta l .
[9] in the Dallas Heart Study (DHS) found an association
between cystatin C and LV mass, concentric hypertrophy,
and LV wall thickness after adjusting for cardiovascular risk
factors in a cohort of 2,500 Caucasians and African-Amer-
icans. However, the authors did not ﬁnd signiﬁcant associ-
ation between cystatin C and LV volumes, unlike our study,
perhaps reﬂecting a younger cohort age (DHS, 30 to 65 years
versus MESA 44 to 84 years) and/or shorter duration of
renal dysfunction. An association between mild-moderate
kidney dysfunction and LV hypertrophy was demonstrated
in 4,971 MESA participants using cystatin C-derived GFR,
but the study did not address the association of kidney
dysfunction and LV volumes [10]. The current study extends
and corroborates previous ﬁndings into a larger multisite
multi-ethnic population free of cardiovascular disease by ex-
ploring the relationship between cystatin C and LV volumes
and concentricity with more precise measures of cardiac
structure and function using magnetic resonance imaging.
Koenig et al. [22] studied 1,033 subjects and found a
strongerassociationofcystatinCwithCVDeventscompared
to creatinine or estimated GFR, suggesting that current esti-
matesofrenalfunctiondonotfullyexplainrenaldysfunction
particularly in mild-to-moderate stages. Similarly, Patel et al.
[9] after adjusting for creatinine and GFR in their models
demonstrated signiﬁcant association between cystatin C and
concentric hypertrophy. In this study, we adjusted for known
risk factors and further adjusted for creatinine or creatinine-
estimated GFR and found signiﬁcant association between
cystatin C quartiles and LV parameters, which corroborates
with such previous ﬁndings [9, 22].
The mechanisms of association between cystatin C and
cardiovasculardisease are not fullycharacterized, and several
complementary hypotheses can be envisioned. Renal insuﬃ-
ciency is a known risk factor for heart failure [23], diastolic
dysfunction, and LV remodeling [24]. The risk of cardio-
vascular remodeling attributable to mild-to-moderate renal
insuﬃciency may not be fully captured by current estimates
of renal function such as creatinine, GFR, and creatinine
clearance. Thus, as a more precise marker of renal function
[6], cystatin C is associated with ventricular remodeling.
Second, cystatin C is highly correlated with hypertension
[9], and the observed association between cystatin C and LV
remodeling could be the result of adjustment by imprecise
measures of blood pressure leading to residual confounding.
Finally, cystatin C may play a direct physiologic role and
inﬂuence ventricular remodeling independent of hyperten-
sion and renal function. The balance between cysteine pro-
teases (cathepsins B, S, and K) and cysteine protease inhibi-
tors (cystatin C) has been implicated in pathological LV
remodeling in heart failure [25, 26]. Cathepsins, stored in
lysosomes, are responsible for the physiological digestive
turnover of cellular molecules, and abnormal levels of which
may adversely inﬂuence cardiac remodeling [26]. Although
the mechanism between cystatin C and LV remodeling is
unclear, it is possible that the alteration of the balance bet-
ween these two classes of proteins may contribute to the LV
remodeling process by matrix degradation [26].
The strength of this study includes a large ethnically
diverse population with stringent quality control procedures
and MRI measurements of cardiac structure and function.
The present study extends prior investigations and supports
the view that kidney disease approximated by elevated cys-
tatin C is associated with concentric remodeling. We found
modest changes in LV volumes across higher quartiles of cys-
tatin C after adjustment which was found to be statistically
signiﬁcant. The clinical implications of these ﬁndings are not
yet clear. It remains to be seen whether the pattern of LV
remodeling demonstrated in the current study is associated
with subsequent development of clinical heart failure or
cardiovascular mortality in the MESA cohort.
We acknowledge several limitations. MESA did not
directlymeasureglomerularﬁltrationrate;therefore,wecan-
not be certain that the association between elevated cystatin
ClevelandLVparametersaresolelycausedbyitsapproxima-
tion of impaired GFR. Due to the cross-sectional design, the
studycannotaddressthedirectionoftheassociationbetween
cystatin C and LV remodeling, and the observed associations
could be purely a statistical phenomenon; however, the re-
sultsareconsistentwithprevioussuchobservedrelationships
which point towards a true association. The association ob-
served between cystatin C and LV remodeling could result
f r o md e c r e a s e dr e n a lp e r f u s i o nf r o mar e d u c e dc a r d i a c
output, or structural remodeling of arteries, although these
possibilities were minimized by inclusion of a cardiovascular
disease-free population, though self-reported history may be
imperfect due to recall bias. Although eﬀorts were made to
adjust for known confounders, there remains a possibility
of failure to adjust for unknown confounders or inadequate
adjustment of established risk factors (severity and duration
of hypertension, diabetes) resulting in spurious results due
to residual confounding. Some studies suggest that corticos-
teroids [27] and thyroid function [28] are associated with
cystatinC,andsinceadjustmentwiththesemeasureswasnot6 International Journal of Nephrology
performed, results should be interpreted with caution in this
subset of individuals.
5. Conclusion
Cystatin C levels are inversely associated with LV end dias-
tolic and systolic volumes and directly associated with con-
centricity independent of traditional cardiovascular risk fac-
tors including hypertension in a multi-ethnic population.
This morphometric pattern of concentric LV remodeling
may in part explain previously observed associations bet-
ween cystatin C and diastolic dysfunction, heart failure, and
cardiovascular mortality.
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